_2021-07-09-parp-i-for-non-hrd-population-dr-ryan-spencer-mp4.jpg "2021-07-09 PARP-i for non-HRD population - Dr. Ryan Spencer.mp4 from parp Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 19 min 18 sec
✓ Published: 14-Jul-2021
✓ Published: 14-Jul-2021
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_james-l-gulley-md-phd-on-prostate-cancer-expanding-immunotherapy-options.webp "James L. Gulley, MD, PhD, of the National Cancer Institute, discusses combined treatment approaches showing early evidence of clinical activity: agents such as vaccines or PARP inhibitors that can initiate an immune response, paired with agents such as checkpoint inhibitors that can facilitate the activity of tumor-directed immune cells.")
⏲ 2 min 33 sec ✓ 28-Jan-2018
_ctsc-124-stenoparib-and-covid-19.webp "Stenoparib Publication in MBio JournalnnStenoparib, an inhibitor of cellular poly (ADP-ribose) polymerase (PARP), blocks replication of the SARS-CoV-2 and HCoV-NL63 human coronaviruses in vitro.nnMore info: https://joinpmi.com/ctsc-stenoparib-and-covid-19")
_parp-inhibitors-in-combination-with-nhas.webp "In this GU CONNECT programme from Dr Andrew Armstrong, you'll follow a patient through their prostate cancer journey and explore the clinical implementation of genetic testing and PARP inhibitors in combination with novel hormonal agents (NHAs). It follows Dr Neal Shore's animated video exploring PARPis as monotherapy.nnWatch the animated video and download the accompanying slides for an update on:nn- Efficacy and safety profiles of PARP inhibitors for prostate cancern- The role of genetic testi")
_what-key-factors-impact-prostate-cancer-treatment-decisions.webp "Prostate cancer expert Dr. Channing Paller reviews key variables that impact prostate cancer treatment decisions and explains immunotherapy, PARP inhibitors, and personalized medicine.nnDr. Channing Paller is Director of Prostate Cancer Clinical Research at Johns Hopkins Medicine. Learn more about Dr. Paller here: https://www.hopkinsmedicine.org/profiles/details/channing-paller")
_prostate-cancer-treatment-decisions-how-do-genetic-test-results-impact-your-options.webp "How do genetic test results impact prostate cancer treatment options? Dr. Nima Sharifi explains BRCA mutations, germline genes, and somatic mutations—and discusses when treatment with PARP inhibitors may be appropriate. Dr. Nima Sharifi is Director of the Genitourinary (GU) Malignancies Research Center at the Cleveland Clinic. Learn more here: https://www.lerner.ccf.org/cancerbio/sharifi/")
⏲ 2 min 54 sec ✓ 10-Dec-2020
_an-overview-of-metastatic-breast-cancer-treatment-options.webp "What metastatic breast cancer (MBC) treatment options are available? Dr. Jane Lowe Meisel provides an overview of MBC treatment approaches, including CDK4-6 inhibitors, tyrosine kinase inhibitors, PARP inhibitors, and immunotherapy.nnJane Lowe Meisel, MD is an Associate Professor of Hematology and Medical Oncology at Winship Cancer Institute at Emory University. Learn more about Dr. Meisel here: https://winshipcancer.emory.edu/bios/faculty/meisel-jane-l.html")
_negative-charge-and-poly-adp-ribosylation-a-scientific-animation.webp "A short 2D animation describing how a molecule, PARP-1, binds to DNA during the DNA repair process.")
_wicked-fart.webp "Muesli maketh the man.")
_james-l-gulley-md-phd-on-prostate-cancer-expanding-immunotherapy-options.jpg)
_ctsc-124-stenoparib-and-covid-19.jpg)
_parp-inhibitors-in-combination-with-nhas.jpg)
_what-key-factors-impact-prostate-cancer-treatment-decisions.jpg)
_prostate-cancer-treatment-decisions-how-do-genetic-test-results-impact-your-options.jpg)
_an-overview-of-metastatic-breast-cancer-treatment-options.jpg)
_negative-charge-and-poly-adp-ribosylation-a-scientific-animation.jpg)
_wicked-fart.jpg)
![[+]](/images/menu.gif){kind=small}